Recombinant adenovirus expressing a dendritic cell-targeted melanoma surface antigen for tumor-specific immunotherapy in melanoma mice model

LI-LI GUO, GANG-CHENG WANG, PENG-JIE LI, CUI-MEI WANG and LIN-BO LIU

Department of Plastic Surgery, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 450052, P.R. China

Received September 27, 2016; Accepted June 5, 2017

DOI: 10.3892/etm.2018.6085

Abstract. Viral vectors represent a potential strategy for the treatment of human malignant tumors. Currently, recombinant adenovirus vectors are commonly used as gene therapy vehicles, as it possesses a proven safety profile in normal human cells. The recombinant adenovirus system has an ability to highly express exogenous genes and increase the stability of the carrier, which is only transiently expressed in the host cell genome, without integrating. Malignant melanoma cells are produced by the skin, and melanocyte tumors that exhibit higher malignant degrees lead to earlier transfer and higher mortality. In the present study, a recombinant adenovirus (rAd) was generated to express Anti-programmed death-1 (rAd-Anti-PD-1) and used to investigate the efficacy in melanoma cells and tumors. The results demonstrated that B16-F10 cell growth was significantly inhibited and the apoptosis incidence rate was markedly promoted following rAd-PD-1 treatment. The present study demonstrated that the production of α and β interferon was increased, which led to the induction of dendritic cell (DCs) maturation in rAd-anti-PD-1-treated mice. The present study indicated that rAd-anti-PD-1 exhibited the ability to generate more cluster of differentiation (CD)4+CD8+ T cells and induce a PD-1-specific cytotoxic T lymphocyte through DC-targeted surface antigens in mice. This resulted in a further enhanced recognition of melanoma cells due to DCs being targeted by the rAd-anti-PD-1-encoded PD-1. Notably, mice treated with the rAd-anti-PD-1-targeted PD-1 demonstrated an improved protection compared with tumor-bearing mice from the challenge group treated with a recombinant gutless adenovirus and Anti-PD-1. In conclusion, the present study demonstrated that targeting the melanoma surface antigens via the rAd-anti-PD-1-infected tumor cells enhanced the ability of recombinant adenovirus to induce a potent tumor-inhibitory effect and antigen-specific immune response.

Introduction

Melanoma derived from melanocytes that exhibit the capacity to be more aggressive and a marked resistance to treatment is leading to an increased morbidity (5%) and mortality rates (15%) globally (1). Advanced melanoma has historically been associated with a poor prognosis and a 5-year survival rate of <10% (2,3). The most important clinical features of melanoma in the initial stages (I/II) are the local migration and long distance metastases through the lymph nodes (4,5). In addition, previous studies have demonstrated that melanoma frequently metastasized to other organs, which is another factor that contributes to the low survival rate (6,7). Although surgery, conventional and comprehensive treatments may produce modest benefits to patients and improve patients’ survival; clinical trials have indicated that the short survival time of patients with melanoma remained and <15% of patients survived (8,9). Therefore, investigating a more efficient approach to inhibit the local and long distance migration of melanoma metastases may improve the survival rate of patients.

Programmed death-1 (PD-1) is a type of immunosuppressive molecule that is activated by programmed death receptor 1 (10,11). PD-1 is a member of the cluster of differentiation 28 (CD28) superfamily, which originated and was cloned through the apoptosis of T cells in mice hybridoma (12). Targeting PD-1 immunity against tumors, anti-infection, autoimmune disease and organ transplantation survival have demonstrated marked outcomes in previous studies (13,14). PD-1 ligand L1 and the antibody of PD-1 are able to produce the same effects via binding with PD-1 (15). Notably, a previous study has indicated that PD-1 is expressed on the surface of various malignancies, including hepatoma, non-small cancer lung cell and colon cancer (16). The antibody target for PD-1 (anti-PD-1) was able to inhibit PD-1 expression (17). However, the function of anti-PD-1 and the survival of patients with cancer remain to be elucidated. Furthermore, the role of PD-1 expression on melanoma cells remains unknown. The present study investigated the therapeutic effects of anti-PD-1 in a mouse model of melanoma. Tumor-bearing mice were used to evaluate the efficacy of anti-PD-1 and the overall survival
according to PD-L1 status in mice with melanoma was assessed by meta-analysis.

Previous studies have indicated that a recombinant adenovirus constructed based on the Adeno-X expression system, resulted in a gene therapy vehicle to treat human cancer (18,19). Adenovirus vectors are one of the most widely used vectors in gene therapy applications for the treatment of diverse human diseases, including cancer (20). The immunotherapy accompanied with other therapeutic methods has revealed therapeutic effects in animal models and different clinical trials (21-23). The use of antineoplastic drugs combined with immunotherapy has been demonstrated to effectively target tumor cells with specific recognition molecules or domains of antigens or receptors (24-27). A number of different agents for the treatment of cancer, including chemoradiotherapy and immunotherapy, are being assessed in preclinical trials (28,29). Immunotherapy agents, in which an antibody or interleukin is inserted into a gene expression vector, have led to positive outcomes regarding tumor apoptosis in patients with advanced tumors pre-clinically and clinically (30). The most crucial area of gene therapy is to establish an effective gene delivery system. In the present study, the oncolytic adenovirus-mediated gene therapy system expressing anti-PD-1 was investigated as a treatment for melanoma-bearing mice.

Development of novel and effective clinical protocols for cancer therapy is urgently required in modern medicine (31). Previously, immunotherapies against the growth and metastasis of tumor cells have been revealed to be a potentially promising approach for the treatment of human cancer (32). The antitumor efficacy of the T cell immune response depends on the exposure of tumor antigens and activities of antigen-presenting cells, which may efficiently present tumor antigens leading to the activation of cytotoxic T lymphocytes. Notably, oncolytic adenovirus expressing interferon-γ (IFN-γ) resulted in significant tumor growth suppression in a syngeneic Syrian hamster model for the treatment of pancreatic cancer (33). This in turn, eradicates corresponding tumor cells. In addition, immunotherapies are activated by dendritic cells (DCs) loaded with tumor surface antigens including tumor cell lysates, nucleic acids encoding tumor antigens, tumor-specific proteins, apoptotic bodies and necrotic tumor cells. A number of research papers have demonstrated a strategy for producing mature DCs, influenced by tumor phenotype and immune responses for eradicating tumor cells. Furthermore, targeting the tumor specific antigens by treating the antibody specific to the DC-restricted antigen may elevate exposure of the tumor specific antigen. This may promote recognition of tumor specific antigens resulting in a limitation in tumor capacity (34,35). The present study demonstrated that the targeting of the melanoma antigen to DC cells via anti-PD-1 expressed by recombinant adenovirus expressing (rAd)-PD-1 markedly promoted the ability of rAd to induce responses from melanoma antigen-specific cytotoxic T lymphocytes.

Materials and methods

Cells and reagents. Melanoma cell lines, B16-F10 and SkMel-2, and a normal human epidermal cell line (NHEC; NHEK) were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA) and cultured in minimum essential media (MEM) supplemented with 10% fetal bovine serum (both from Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 2 mM penicillin/streptomycin (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) in a humidified incubator at 37°C and 5% CO₂.

Construction of recombinant adenovirus. An adenox-expression system (A4470; Sigma-Aldrich; Merck KGaA) (36) was used to construct the recombinant adenovirus constructs. DNA sequence (GenBank, NM_008798.2) encoding full-length Anti-PD-1 linked with the cell-penetrating peptide and Fc was cloned into the rAd-X plasmids (A4470; Sigma-Aldrich; Merck KGaA) by polymerase chain reaction (PCR) using KAPA Taq PCR kit with dNTPs (cat. no. TAQNTKB; Sigma-Aldrich; Merck KGaA). The primers were as follows: PD-1 forward, 5'-TCGATCTGGAACTGTGGCCAT-3' and reverse, 5'-TGCCCAAGGGCCTGTGGATCTAA-3'. Then, the recombinant adenoviral plasmid rAd-anti-PD-1 and rAd-enhanced green fluorescent protein (rAd-EGFP, produced in our laboratory) were produced by PCR as described previously for subsequent analysis. PCR and sequencing (Invitrogen; Thermo Fisher Scientific, Inc.) were used to identify recombinant adenovirus constructs. Thermocycling of PCR was performed using PCR kit (11696505001; Sigma-Aldrich; Merck KGaA) as follows: 95°C for 1 min; and 25 cycles of 94°C for 30 sec, 56°C for 1 min and 72°C for 1 min. The recombinant adenoviruses were generated by transfecting into HEK293 cells using Lipofectamine 2000 (Sigma-Aldrich; Merck KGaA) according to manufacturers' instructions and underwent culture in DMEM at 37°C in an atmosphere containing 5% CO₂. The recombinant adenovirus constructs were purified as described in a previous study (18). Adenovirus titers were determined by TCID₅₀ as plaque-forming units/ml using the Reed-Muench method (37).

MTT assay. B16-F10 and SkMel-2 cells (1x10⁵) were cultured and then inoculated with rAd-Anti-PD-1 [0.5 multiplicity of infection (MOI)] or rAd-EGFP 0.5 (MOI) or PBS in 96-well plates for 48 h at 37°C in triplicate for each condition. Following culture, 20 µl MTT (5 mg/ml) in PBS solution was added to each well, the plate was further incubated for 4 h at 37°C. The medium was entirely removed and 100 µl dimethyl sulfoxide was added to the wells to solubilize the crystals. The optical density (OD) was measured using an ELISA microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA) reader at a wavelength of 450 nm.

Cells morphology. B16-F10 and SkMel-2 cells (5x10⁴) were cultured in six-well plate and treated with rAd-Anti-PD-1 (0.5 MOI), rAd-EGFP, rAd or vehicle (Mock) in 6-well plates for 48 h at 37°C. The cells were cells morphology was observed by a microscope (Nikon E400, Nikon Instrument Group, Japan). The EGFP fluorescence was observed using a confocal microscope (magnification, x40; Olympus FV10; Olympus, Tokyo, Japan).

Reverse transcription-quantitative PCR (RT-qPCR). Total RNA was extracted from B16-F10 and SkMel-2 cells using
Cells invasion and migration assays. B16-F10 and SkMel-2 cells were cultured in DMEM medium at 37°C in an atmosphere containing 5% CO₂ and treated with rAd-Aiti-PD-1 (0.5 MOI), rAd-EGFP (0.5 MOI) or PBS as a control. For the invasion assay, virus-treated cells were suspended at a density of 1x10⁶ cells/ml in serum-free MEM and then transferred to the upper chamber of a BD BioCoat Matrigel Invasion Chamber (BD Biosciences, San Jose, CA, USA) according to the manufacturer's instructions. The cells were fixed using methanol for 30 min at 37°C and stained for 30 min in a 0.1% Crystal Violet solution in PBS at 37°C. Invasion and migration were calculated in at least three random fields of view under a microscope (Nikon E400; magnification, x20; Nikon Instrument Group, Tokyo, Japan).

Animal study. A total of 80 eight-week-old male specific-pathogen-free C57BL/6 nude immunodeficiency mice (30-35 g) were purchased from Shanghai Laboratory Animal Centre (Shanghai, China). All animals were housed in a temperature-controlled facility at 23±1°C (humidity, 50±5%) with a 12-h light/dark cycle. All rats had free access to food and water. A total volume of 100 µl B16-F10 cells (1x10⁶) were administered subcutaneously into a site on the back of the C57BL/6 mice. C57BL/6-bearing mice were randomly divided into four groups and received treatment of rAd-Aiti-PD-1 (0.5 MOI), rAd-EGFP (0.5 MOI), rAd (0.5 MOI) or PBS (n=20 in each group). The therapy (rAd, rAd-EGFP or rAd-anti-PD-1, 5 MOI) was initiated on day 6 when tumor diameters reached 5-6 mm and mice were treated 10 times for a period of 20 days (i.e., every other day). Mice were sacrificed when tumor diameters reached 12 mm. Tumor diameters were recorded every 2 days and tumor volume was calculated as follows: \( V = \frac{4}{3} \pi \times d_1 \times d_2 \times d_3 \) (39). The present study was performed according to the recommendations in the Guide for the Care and Use of Laboratory Animals (40). All experiments were completed in accordance with National Institutes of Health and approved by Committee on the Ethics Committee of Zhengzhou University (Zhengzhou, China). All surgeries and euthanasia were performed under sodium pentobarbital anesthesia (40 mg/kg) when tumor diameter reached 16 mm.

Splenocyte collection and cytotoxic T lymphocyte (CTL) responses. Splenocytes were extracted from spleens of the experimental animals using cell separation method described previously (41) (n=4 in each group) on day 30 after tumor incubation. The monoplas suspension was washed three times with PBS three times at 37°C. Release of interferon (IFN) was evaluated by ELISA (DY485, Bio-Rad Laboratories, Inc., Hercules, CA, USA) in the supernatants following culture for 72 h. T cells (1x10⁶) from spleenocytes were purified, as previously described (32) and co-cultured with fresh DMEM B16-F10 cells for 4 h at 37°C at the effector, at target ratios of 5:1, 20:1 and 40:1, which were ratios used in a previous study (42). Specific CTL activity to the target cells was determined by MTT cytotoxicity assays, as previously described (43).

Western blot analysis. B16-F10 and SkMel-2 cells (1x10⁶) were cultured, lysed and used to analyze PD-1 expression according to a previous study (44). Cells were homogenized in lystate buffer containing protease-inhibitor (Sigma-Aldrich; Merck KGaA) and were centrifuged at 8,000 x g at 4°C for 10 min. Protein concentration was measured using the BCA protein assay kit (Thermo Scientific Fisher Scientific, Inc.). Protein samples (20 µg per lane) were separated using 15% SDS-PAGE and transferred onto polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). Following this, blocking with 5% bovine serum albumin was performed at 37°C for 1 h. The following primary antibodies were used in immunoblotting assays: PD-1 (1:1,000, cat. no. ab65777) and β-actin (1:1,000, cat. no. ab8226; all from Abcam, Cambridge, UK) for 12 h at 4°C. Horseradish peroxidase-conjugated antibody (1:5,000; cat: no: HAF019, Bio-Rad Laboratories, Inc.) was used as a secondary antibody for 2 h at 37°C. Subsequently, bands were detected using a western blotting luminol reagent (cat. no. 12015218001; Sigma-Aldrich; Merck KGaA). The density of the bands was analyzed by Quantity one software version 4.62 (Bio-Rad Laboratories, Inc.).

Histological analysis. Tumor tissues from experimental mice were fixed using 10% formaldehyde for 2 h at 37°C followed by being embedded in paraffin. Tumor samples were cut into sections (4 µm) and antigen retrieval (at 95°C for 15 min) was also performed on tumor sections. Tumor sections were incubated with primary antibodies: PD-1 (1:1,000, ab214421, Abcam, Cambridge, MA, USA) and β-actin (1:1,000, ab8226, Abcam). Subsequently, sections were incubated with horse-radish peroxidase (HRP)-conjugated polyclonal anti-rabbit immunoglobulin G antibody (1:10,000; R&D Systems, Inc., Minneapolis, MN, USA) for 1 h at room temperature. A Ventana Benchmark automated staining system (Ventana Medical Systems, Inc.; Roche Holding AG, Basel, Switzerland)
was used for observing the protein expression (Olympus BX51, Olympus; Tokyo, Japan; magnification, x20).

Statistical analysis. All data were reported as means ± standard error of the mean from triplicate experiments. Data was analyzed using GraphPad Prism 6.0 software (GraphPad Software, Inc., La Jolla, CA, USA). Unpaired data was analyzed by Student’s t-test. Comparisons of data between multiple groups were analyzed by one-way analysis of variance followed by Tukey HSD test. P<0.05 was considered to indicate statistically significant differences.

Results

Characterization of the recombinant adenovirus constructs. The recombinant adenovirus constructs delivering the Anti-PD-1 or EGFP were generated based on the adeno-X expression system. The description of adenovirus constructs is presented in Fig. 1A. In order to investigate whether the insertion of the foreign gene in the adeno-X expression system affected the growth of the virus, the kinetic growth of recombinant adenovirus constructs was analyzed. The result in Fig. 1B demonstrated that similar virus titers were observed; indicating that insertion of the foreign gene in the adeno-X expression system do not affect viral growth and expression in tumor cells.

**rAd expressing Anti-PD-1 targeted PD-1 and effectively enhanced the lysis of human and murine melanoma cell lines.** The PD-1 expression in B16-F10 and SkMel-2 cells was further assessed using RT-qPCR. The results indicated that PD-1 expression was higher in B16-F10 and SkMel-2 cells compared with NHECs (P<0.01; Fig. 2A). Notably, rAd-anti-PD-1 significantly decreased the expression of PD-1 at 48 h following inoculation (P<0.05; Fig. 2B). To further confirm that the anti-PD-1 protein exhibited a higher expression in tumor cells infected by rAd-anti-PD-1, the present study performed a time course of rAd-anti-PD-1 infection in B16-F10 cells. The results in Fig. 2C indicate that anti-PD-1 was detected as early as 6 h following infection with rAd-anti-PD-1 at 0.1 MOI. Furthermore, rAd-anti-PD-1 effectively lysed melanoma cell lines compared with rAd-EGFP and rAd (Fig. 2D). Taken together, these results suggest that rAd-anti-PD-1 is efficiently expressed in tumor cells and was able to downregulate PD-1 expression.

**rAd expressing Anti-PD-1 enhanced antitumor efficacy in B16-F10-xenograft mice.** In order to detect the inhibitory effects of rAd-Anti-PD-1, tumor cell growth was analyzed in vitro. The growth of B16-F10 cells was significantly inhibited following rAd-Anti-PD-1 treatment at 0.5 MOI for 48 h compared with rAd and rAd-EGFP (P<0.01; Fig. 3A). In
addition, invasion of B16-F10 and SkMel-2 cells was significantly suppressed when treated with rAd-Anti-PD-1 at 0.5 MOI for 48 h compared with rAd and rAd-EGFP (P<0.01; Fig. 3B). Subsequently, the efficacy of antitumor treatment with rAd-Anti-PD-1 was investigated in B16-F10-bearing mice. Animals were administered treatment of rAd, rAd-EGFP, rAd-PD-1 or PBS as control by intravenous injection. These results demonstrate that rAd and rAd-EGFP treatment significantly inhibited tumor growth, compared with PBS as a control. Notably, a significant inhibition of tumor growth was observed with rAd and compared with rAd-anti-PD-1 (P<0.01; Fig. 3C). Furthermore, the 240-day long-term survival following treatment with rAd-anti-PD-1 was assessed and demonstrated that treatment with rAd-Anti-PD-1 (n=20) significantly prolonged the survival of mice compared with other groups (P<0.01; Fig. 3D). Collectively, these results reveal that rAd-Anti-PD-1 significantly inhibited melanoma cell growth in vitro and in vivo, suggesting that the use of oncolytic therapy with rAd-anti-PD-1 against melanoma contributed to long-term survival of melanoma-bearing mice.

Induction of rAd-Anti-PD-1-specific cellular immune responses. A previous study indicated that presenting tumor antigen by DC is essential in order to activate cytotoxic T lymphocytes to inhibit the invasion of tumor cells (45). Therefore, the present study analyzed the expression of B16-F10-sepcific tumor antigen and DC cells on the surface of tumor cells 21 days following tumor inoculation. The results indicated that the expression of tumor antigens and DC cells was elevated in rAd-anti-PD-1-treated tumors (Fig. 4A). The present study also revealed that PD-1 expression was markedly decreased, whereas apoptotic bodies were increased in tumors following rAd-anti-PD-1 treatment (Fig. 4B). In addition, the cytotoxic T lymphocyte response in rAd-Anti-PD-1-treated mice was also detected. As presented in Fig. 4C, the production of IFN-α and IFN-β increased, which contributed to induce the maturation of DCs in rAd-Anti-PD-1-treated mice. Furthermore, the results of the present study demonstrated that rAd-Anti-PD-1 exhibited the ability to generate significantly more CD4+ and CD8+ T cells and induce a PD-1-specific CTL through DC-targeted surface antigens in mice that resulted in further enhancing recognition melanoma cells by the targeting of the rAd-anti-PD-1-encoded PD-1 to DCs (P<0.05; Fig. 4D and E). The present study revealed that melanoma-bearing mice treated with the rAd-Anti-PD-1-targeted PD-1 were significantly more protected against apoptosis than tumor-bearing mice following challenge with Anti-PD-1 (Fig. 4F). Collectively, the results of the present study confirmed the hypothesis and suggested that rAd-anti-PD-1 activated immunotherapy by inducing DC
maturation in melanoma, which contributed to tumor regression and long-term survival.

Discussion

Previous studies have indicated that gene therapy may provide an improved clinical method for treating melanoma, and these therapies were considered as potential adjuvants for other cancer therapies (46,47). Adenovirus vectors are the most widely used treatment and Adenovirus-mediated delivery of functional genes or polypeptides into tumor cells is well understood (48). Additionally, gene transfer strategies have led to more clinicians using immunotherapy to treat patients with HCC, including inhibition of oncogenes and restoration of tumor-suppressor genes, immunotherapy, anti-angiogenesis and virotherapy (49). Therefore, the present study may provide a more effective therapy for melanoma tumors by delivering PD-1 via a recombinant adenovirus. The results of the present study indicated that PD-1 expressed by recombinant adenovirus induced the accumulation of DCs, which could expose tumor antigens and promote T lymphocyte-induced tumor cytotoxicity.

Gene therapy has previously identified potential candidates for the treatment of human diseases including cancer, cardiovascular disease, blood diseases, diabetes, genetic diseases and other diseases that cannot be treated with conventional drug therapies (50-52). Previously, the use of viral vectors to deliver vectors to express functional genes has been applied in different medical fields, including cancer therapy and cardiovascular disease. These oncolytic viral vectors have been demonstrated to be relatively safe due to a selectively to replicate in cancer cells, but not in normal cells (53,54). The benefits of these oncolytic viral vectors are that as they replicate and lyse tumor cells, and functional genes delivered by oncolytic viral vectors strengthen the effects of tumor eradication and inhibit the chance of recurrence (55). Adenovirus, Newcastle disease virus and herpes simplex virus are the most commonly used gene therapy oncolytic viral vectors, as vectors that specifically mutate and selectively replicate faster in cancer cells (56). The Adeno-X expression system is the most commonly used and >250 patients have been treated with ONYX-015 (a replicating adenovirus) (57). In the present study, the Adeno-X expression system was used to deliver an antibody of PD-1 to assess the oncolytic effects of a recombinant virus in melanoma in vitro and in vivo.

CTL-associated PD-1 inhibitors are well understood and represent one of the most important immunomodulating agents (58). PD-1 receptor or antibody are well tolerated and exhibit a low rate of adverse effect recurrence, as demonstrated in a previous study (58). In addition, a study has demonstrated that antibodies targeting PD-1 signaling promote a T-cell-mediated antitumor therapy and prevent tumor invasion (59). The present study revealed that anti-PD-1 demonstrated a significant inhibition of melanoma cells growth and a marked increase of DC cell maturation to present melanoma-specific antigens for cytotoxic T lymphocyte-associated immunotherapy. A previous study indicated that DC cell maturation is an essential step for the development of anti-cancer
immunotherapy and induction of the cytotoxic T-cell immune responses in the majority of tumor cells (60). The data from the present study has identified that rAd-anti-PD-1 recognized PD-1 in tumor cells of mice with melanoma and decreased the expression of PD-1 and enhanced the infiltration of T cells. Although the induction of tumor cell apoptosis due to PD-1 inhibition or antibodies in patients with metastatic melanoma has been investigated, the PD-1 signaling pathway remains to be elucidated. Notably, the present study revealed that anti-PD-1, delivered by rAd-anti-PD-1, induces DC maturation and presents more melanoma-specific antigens for antitumor responses, which contribute to improved long-term survival. This may potentially lead to marked antitumor responses through activation of the immune system.

In conclusion, the present study demonstrates that full-length Anti-PD-1 may be expressed by rAd-Anti-PD-1-infected

Figure 4. rAd-anti-PD-1 enhanced DCs to present melanoma tumor antigen. (A) Expression of tumor antigens and DC cells was assessed in tumors from experimental mice on day 30 (magnification, x40). (B) Expression of PD-1 and apoptotic bodies in tumors were analyzed after treatment with recombinant adenovirus (magnification, x40). (C) IFN levels were analyzed after treatment with recombinant adenovirus. (D) Level of CD4+CD8+ T cells were assessed in tumors during treatment on day 30. (E) Analysis of the CTL responses in melanoma-bearing mice treated with the rAd-Anti-PD-1. (F) Tumor challenge experiment analyzed the long-term efficacy of rAd-anti-PD-1 treatment. Data are presented as mean ± standard error of the mean. *P<0.01 vs. control. rAd, recombinant adenovirus expressing; PD-1, programmed death-1; DC, dendritic cells; IFN, interferon; CD, cluster of differentiation; CTL, cytotoxic T lymphocyte; PBS, phosphate-buffered saline; EGFP, enhanced green fluorescent protein.
tumor cells and inhibits the growth and invasion of melanoma cells. In addition, the most notable finding in the present study is that anti-PD-1 expressed by rAd-anti-PD-1-infected tumor cells induces the maturation of DCs, which to the best of our knowledge has not been reported in previous studies. The rAd-anti-PD-1 virus is associated with a number of antitumor capacities and largely inhibits tumor growth in vivo, indicating its potential antitumor effects. Furthermore, rAd-anti-PD-1 induced the DC-presenting tumor antigen and promoted a more potent CTL in the immune response. Taken together, the use of DC-presenting tumor antigens as a strategy of rAd-anti-PD-1 may represent a potential strategy of combining the oncolytic efficacy of adenovirus and present tumor antigen in addition to CTL, which enhance the anti-melanoma potency.

References